1307273-65-9

Upstream product

• 98-88-4 benzoyl chloride 
• 100-39-0 benzyl bromide 
• 1307273-57-9 (3R,6R,6aR)-6-(tert-butoxymethyl)-2,2-dimethyl-5-methylenedihydro-3aH-cyclopenta[d][1,3]-dioxol-4-(5H)one 
• 1338348-10-9 C₁₄H₁₇FO₃ 
• 1307273-61-5 (-)-(6aR,8S,9S,9aR)-8-(benzyloxy)-2,2,4,4-tetraisopropyl-7-methylenehexahydrocyclopenta[f][1,3,5,2,4]trioxadisilocin-9-ol 
• 1307273-60-4 (-)-(1R,2R,3S,5R)-3-(benzyloxy)-5-(hydroxymethyl)-4-methylenecyclopentane-1,2-diol 
• 1307273-59-1 (-)-(3aR,4S,6R,6aR)-4-(benzyloxy)-6-(tert-butoxymethyl)-2,2-dimethyl-5-methylenetetrahydro-3aH-cyclopenta[d][1,3]dioxole 
• 1307273-58-0 (3aS,4S,6R,6aR)-6-(tert-butoxymethyl)-2,2-dimethyl-5-methylenetetrahydro-3aH-cyclopenta[d][1,3]-dioxol-4-ol 
• 1307273-63-7 (-)-(6aR,8S,9R,9aR)-8-(benzyloxy)-9-fluoro-2,2,4,4-tetraisopropyl-7-methylenehexahydrocyclopenta[f][1,3,5,2,4]trioxadisilocine 
• 1307273-62-6 (-)-(6aR,8S,9R,9aR)-8-(benzyloxy)-2,2,4,4-tetraisopropyl-7-methyleneperhydrocyclopenta[f][1,3,5,2,4]trioxadisilocin-9-ol 
• 223596-25-6 (3aR,6R,6aR)-6-(tert-butoxymethyl)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-one 

Downstream Products

• 1307273-69-3 C₂₆H₂₂FN₅O₄ 
• 1307273-71-7 (+)-9-[(1R,2R,3R,4R)-2-fluoro-3-benzyloxy-4-(benzyloxymethyl)-5-methylenecyclopentan-1-yl]-6-N,N-di-Boc-adenine 

Relevant academic research and scientific papers

Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants

Novel 2'-fluoro-6'-methylene-carbocyclic adenosine (9) was synthesized and evaluated its anti-HBV activity. The titled compound demonstrated significant antiviral activity against wild-type as well as lamivudine, adefovir and double lamivudine/entecavir r

2'-Fluoro-6'-Methylene Carbocyclic Nucleosides and Methods of Treating Viral Infections

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and condit